Clinical trial
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL)…
NCT00330564 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00330564 |
|---|---|
| Title | Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow |
| Official title | A Phase 2 Study of SU011248 (Sunitinib Malate) in Von Hippel-Lindau Syndrome |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Pfizer Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Von Hippel-Lindau Syndrome, Renal Cell Carcinoma, Hemangioblastoma |
| Intervention type | Drug |
| Interventions | SU011248 |
| Enrollment | 15 |
| Start date | May 1, 2006 |
| Primary completion | May 1, 2011 |
| Completion | May 1, 2011 |
| First posted | May 29, 2006 |
| Last update posted | Jun 27, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: